HC Wainwright Has Bearish Estimate for HRMY FY2025 Earnings

Key Points

• HC Wainwright has revised its earnings per share (EPS) estimate for Harmony Biosciences' FY2025 from $3.83 to $3.55, with consensus estimates for the current year at $2.43 per share.
• In its latest quarterly earnings report, Harmony Biosciences posted an EPS of $0.68, missing the consensus estimate of $0.78, while revenue was reported at $200.49 million, below expectations of $204.37 million.
• Despite recent earnings concerns, multiple analysts have issued buy ratings, with an average target price of $51.00 for the stock, reflecting mixed sentiment among analysts about the company's future performance.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Investment analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for Harmony Biosciences in a report released on Wednesday, August 6th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $3.55 for the year, down from their prior forecast of $3.83. The consensus estimate for Harmony Biosciences' current full-year earnings is $2.43 per share. HC Wainwright also issued estimates for Harmony Biosciences' Q1 2026 earnings at $0.75 EPS, FY2026 earnings at $4.08 EPS and FY2027 earnings at $5.00 EPS.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, missing analysts' consensus estimates of $0.78 by ($0.10). The company had revenue of $200.49 million during the quarter, compared to the consensus estimate of $204.37 million. Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%. Harmony Biosciences's revenue was up 16.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.05 earnings per share.

Several other equities research analysts have also issued reports on HRMY. Truist Financial began coverage on Harmony Biosciences in a research note on Monday, July 21st. They set a "buy" rating and a $48.00 price objective for the company. UBS Group dropped their price objective on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a research note on Monday, April 28th. Needham & Company LLC reaffirmed a "buy" rating and set a $49.00 price objective on shares of Harmony Biosciences in a report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a $55.00 target price (up from $54.00) on shares of Harmony Biosciences in a research report on Thursday, July 10th. Finally, The Goldman Sachs Group assumed coverage on Harmony Biosciences in a research note on Thursday, July 10th. They set a "neutral" rating and a $33.00 price target for the company. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $51.00.

Harmony Biosciences Price Performance

NASDAQ:HRMY opened at $34.19 on Monday. The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of 11.03, a P/E/G ratio of 0.40 and a beta of 0.84. Harmony Biosciences has a 52-week low of $26.47 and a 52-week high of $41.61. The stock has a fifty day moving average of $34.16 and a 200 day moving average of $33.78. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.80 and a current ratio of 3.84.

Institutional Investors Weigh In On Harmony Biosciences

Several hedge funds have recently added to or reduced their stakes in HRMY. JPMorgan Chase & Co. lifted its stake in Harmony Biosciences by 2.4% during the fourth quarter. JPMorgan Chase & Co. now owns 235,882 shares of the company's stock worth $8,117,000 after purchasing an additional 5,454 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Harmony Biosciences by 7.0% in the fourth quarter. Franklin Resources Inc. now owns 31,869 shares of the company's stock worth $1,097,000 after buying an additional 2,096 shares during the period. Geode Capital Management LLC increased its holdings in shares of Harmony Biosciences by 22.8% in the fourth quarter. Geode Capital Management LLC now owns 902,934 shares of the company's stock worth $31,077,000 after buying an additional 167,516 shares during the period. Envestnet Asset Management Inc. increased its holdings in shares of Harmony Biosciences by 2.5% in the fourth quarter. Envestnet Asset Management Inc. now owns 53,826 shares of the company's stock worth $1,852,000 after buying an additional 1,321 shares during the period. Finally, FMR LLC increased its holdings in shares of Harmony Biosciences by 1.9% in the fourth quarter. FMR LLC now owns 5,329,902 shares of the company's stock worth $183,402,000 after buying an additional 101,182 shares during the period. Institutional investors own 86.23% of the company's stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.